Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | David C. Smith, Michael Gordon, Wells Messersmith, Rashmi Chugh, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Rainer K. Brachmann, and Antonio Jimeno | ||||||||||||
Title | A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/12/11_Supplement/B79.short | ||||||||||||
Abstract Text | Mol Cancer Ther 2013;12(11 Suppl):B79 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ipafricept | Ipafricept | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ipafricept | Fzd8-Fc|OMP-54F28 | WNT Inhibitor 15 | Ipafricept (OMP-54F28) is a fusion protein comprised of the ligand binding domain of the Frizzled family receptor 8 and the human immunoglobulin Fc domain, which binds Wnt and prevents downstream signaling, thereby inhibiting tumor growth (PMID: 25172549, PMID: 32694153, PMID: 31174889). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|